AstraZeneca Pharmaceuticals LP et al. v. Anchen Pharmaceuticals Inc. et al.

AstraZeneca Pharmaceuticals LP et al. v. Anchen Pharmaceuticals Inc. et al.

D.N.J. (2012)

Fitzpatrick Successfully Defends Drug Seroquel XR® on Behalf of Client AstraZeneca

On March 29, 2012, after facing a patent challenge by four generic drug manufacturers in a Hatch-Waxman lawsuit, Fitzpatrick successfully defended AstraZeneca Pharmaceuticals’ blockbuster antipsychotic drug Seroquel XR®.

After a 12 day trial, U.S. District Judge Joel A. Pisano in New Jersey ruled that generic makers Anchen, Osmotica, Torrent and Mylan infringed AstraZeneca’s patent on sustained release quetiapine, and rejected the defenses that the patent was invalid. The Court entered a permanent injunction against all four generic manufacturers until May 28, 2017, when the patent expires. U.S. sales of Seroquel XR® have totaled $1.7 billion from 2007 through March 2011.

AstraZeneca’s litigation team was led by Fitzpatrick partners Henry J. Renk, Bruce C. Haas, Steven C. Kline, and Michael P. McGraw, with associates Dennis Gregory, Anna Huang, Robert J. Czarnecki, Joshua A. Davis, Gabrielle Markeson, Soma Saha and Raghav Kohli.